PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of atezolizumab for alveolar soft part sarcoma, epcoritamab for follicular lymphoma, and isatuximab for multiple myeloma in Japan

被引:0
作者
Matsumura, Noriomi [1 ,2 ]
Mandai, Masaki [2 ,3 ]
机构
[1] Kindai Univ, Fac Med, Osaka, Japan
[2] Japan Soc Clin Oncol, Editorial Comm, Tokyo, Japan
[3] Kyoto Univ, Grad Sch Med, Kyoto, Japan
关键词
D O I
10.1007/s10147-025-02741-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:825 / 826
页数:2
相关论文
共 6 条
[1]  
Endo M, 2023, CONN TISS ONC SOC M
[2]   Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].
Facon, Thierry ;
Dimopoulos, Meletios-Athanasios ;
Leleu, Xavier P. ;
Beksac, Meral ;
Pour, Ludek ;
Hajek, Roman ;
Liu, Zhuogang ;
Minarik, Jiri ;
Moreau, Philippe ;
Romejko-Jarosinska, Joanna ;
Spicka, Ivan ;
Vorobyev, Vladimir I. ;
Besemer, Britta ;
Ishida, Tadao ;
Janowski, Wojciech ;
Kalayoglu-Besisik, Sevgi ;
Parmar, Gurdeep ;
Robak, Pawel ;
Zamagni, Elena ;
Goldschmidt, Hartmut ;
Martin, Thomas G. ;
Manier, Salomon ;
Mohty, Mohamad ;
Oprea, Corina ;
Bregeault, Marie-France ;
Mace, Sandrine ;
Berthou, Christelle ;
Bregman, David ;
Klippel, Zandra ;
Orlowski, Robert Z. .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (17) :1597-1609
[3]  
Genmab, 2025, EPKINLY EPCORITAMAB
[4]   Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study [J].
Linton, Kim M. ;
Vitolo, Umberto ;
Jurczak, Wojciech ;
Lugtenburg, Pieternella J. ;
Gyan, Emmanuel ;
Sureda, Anna ;
Christensen, Jacob Haaber ;
Hess, Brian ;
Tilly, Herve ;
Cordoba, Raul ;
Lewis, David John ;
Okada, Craig ;
Hutchings, Martin ;
Clausen, Michael Roost ;
Sancho, Juan-Manuel ;
Cochrane, Tara ;
Leppa, Sirpa ;
Chamuleau, Martine E. D. ;
Gernhardt, Diana ;
Altintas, Isil ;
Liu, Yan ;
Ahmadi, Tahamtan ;
Dinh, Minh H. ;
Hoehn, Daniela ;
Favaro, Elena ;
Elliott, Brian ;
Thieblemont, Catherine ;
Vose, Julie M. .
LANCET HAEMATOLOGY, 2024, 11 (08) :e593-e605
[5]  
Pharmaceuticals and Medical Devices Agency, 2024, LIST APPROVED DRUGS
[6]  
Pharmaceuticals and Medical Devices Agency, 2025, REVISIONS PRECAUTION